Table 1.

Demographic and clinical characteristics of melanoma patients treated with immunotherapy

Variable	Number of patients (n = 18)
Age (years)
Median (range)	41 (25–67)
Gender
Male	10 (55.5 %)
Female	8 (44.4 %)
Type of immunotherapy
TriMixIpi	11 (61.1 %)
Ipi	7 (38.8 %)
Response to immunotherapy
DB	5 (27.7 %)
NB	13 (72.2 %)

Ipi Ipilimumab;TriMixIpi TriMixDC combined with Ipi; TriMixDC DC electroporated with mRNA encoding CD70, CD40L and a constitutively active toll-like receptor 4, co-electroporated with mRNA encoding full-length MAGE-A3, MAGE-C2, tyrosinase and gp100; DB durable clinical benefit; NB no clinical benefit